References
- Akajagbor, D. S., Wilson, S. L., Shere-Wolfe, K. D., Dakum, P., Charurat, M. E., Gilliam, B. L. (2013). Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin b in critically ill patients at a tertiary care medical center. Clin. Infect. Dis., 57 (9), 1300–1303.
- Anonymous (2015). European Medicines Agency completes review of polymyxin-based medicines. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Polymyxin_31/WC500176333.pdf
- Anonymous (2016). Consensus Guidance on High Dose Colistimethate Sodium (Colistin) in Management of Carbapenemase produsing enterobacteriaceae (CPE) in Adults. Available from: https://www.scottishmedicines.org.uk/files/sapg/SAPG_High_Dose_Colistin_Treatment_in_Adults_Consensus_Guidance.pdf
- Balkan, I. I., Dogan, M., Durdu, B., Batirel, A., Hakyemez, I. N., Cetin, B., Karabay, O., Gonen, I., Ozkan, A. S., Uzun, S., Demirkol, M. E., Akbas, S., Kacmaz, A. B., Aras, S., Mert, A.,Tabak, F. (2014). Colistin nephrotoxicity increases with age. Scand. J. Infect. Dis., 46, 678–685.
- Dalfino, L., Puntillo, F., Mosca, A., Monno, R., Spada, M. L., Coppolecchia, S., Miragliotta, G., Bruno, F., Brienza, N. (2012). High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategy? A preliminary study. Clinical Infectious Diseases?: An Official Publication of the Infectious Diseases Society of America. Clin. Infect. Dis., 54 (12), 1720–1726.
- Dhariwal, A. K., Tullu, M. S. (2013). Colistin: Re-emergence of the “forgotten” antimicrobial agent. J. Postgr. Med., 59, 208–215.
- Garonzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., Nation, R. L. (2011). Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother., 55 (7), 3284–3294.
- Gauthier, T. P., Wolowich, W. R., Reddy, A., Cano, E., Abbo, L., Smith, L. B. (2012). Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob. Agents Chemother., 56 (5), 2392–2396.
- Honore, P. M., Jacobs, R., Joannes-Boyau, O., Boer, W., De Waele, E., Van Gorp, V., Spapen, H. D. (2013). Continuous renal replacement therapy allows higher colistin dosing without increasing toxicity. J. Transl. Intern. Med., 1 (1), 6–8.
- Javan, O., Shokouhi, S., Sahraei, Z. (2015). A review on colistin nephrotoxicity. Eur. J. Clin. Pharmacol., 71 (7), 801–810.
- Kassamali, Z., Rotschafer, J. C., Jones, R. N., Prince, R. A., Danziger, L. H. (2013). Polymyxins: Wisdom does not always come with age. Clin. Infect. Dis., 57 (6), 877-883.
- Nation, R. L., Garonzik, S. M., Li, J., Thamlikitkul, V., Giamarellos-Bourboulis, E. J., Paterson, D. L., Turnidge, J. D., Forrest, A., Silveira, F. P. (2016). Updated US and European dose recommendations for intravenous colistin: How do they perform? Clin. Infect. Dis., 62 (5), 552–558.
- Omrani, A. S., Alfahad, W. A., Shoukri, M. M., Baadani, A. M., Aldalbahi, S., Almitwazi, A. A., Albarrak, A. M. (2015). High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Ann. Clin. Microbiol. Antimicrob., 14 (3), 1–6.
- Ortwine, J. K., Sutton, J. D., Kaye, K. S., Pogue, J. M. (2015). Strategies for the safe use of colistin. Expert Rev. Anti. Infect. Ther., 13 (10), 1237–1247.
- Plachouras, D., Karvanen, M., Friberg, L. E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., Karaiskos, I., Poulakou, G., Kontopidou, F., Armaganidis, A., Cars, O., Giamarellou, H. (2009). Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob. Agents Chemother., 53 (8), 3430–3436.
- Rocco, M., Montini, L., Alessandri, E., Venditti, M., Laderchi, A., De Pascale, G., Raponi, G., Vitale, M., Pietropaoli, P., Antonelli, M. (2013). Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: A retrospective cohort study. Crit. Care, 17 (4), R174.
- Santamaría, C., Mykietiuk, A., Temporiti, E., Stryjewski, M. E., Herrera, F., Bonvehi, P. (2009). Nephrotoxicity associated with the use of intravenous colistin. Scand. J. Infect. Dis., 41 (10), 767–769.